MeSH term
Frequency | Condition_Probility | Adult | 54 | 0.0 |
Aged | 14 | 0.0 |
Case-Control Studies | 3 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Female | 71 | 0.0 |
Humans | 157 | 0.0 |
Male | 75 | 0.0 |
Middle Aged | 34 | 0.0 |
Research Support, Non-U.S. Gov't | 82 | 0.0 |
Animals | 30 | 0.0 |
Complement/*immunology | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Protein Binding | 5 | 0.0 |
Family Health | 7 | 0.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Time Factors | 6 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Binding Sites | 15 | 0.0 |
Complement Factor H/*chemistry/genetics/*metabolism | 3 | 100.0 |
Hemolytic-Uremic Syndrome/*genetics | 2 | 66.0 |
Heparin/*metabolism | 2 | 2.0 |
Models, Molecular | 4 | 0.0 |
Molecular Sequence Data | 27 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Bacterial Proteins/*metabolism | 5 | 10.0 |
Base Sequence | 14 | 0.0 |
Complement Factor H/*metabolism | 11 | 68.0 |
DNA Primers | 3 | 0.0 |
Risk Factors | 12 | 0.0 |
Statistics | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Odds Ratio | 3 | 0.0 |
Phenotype | 9 | 0.0 |
Adolescent | 22 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Age Factors | 5 | 0.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Genotype | 8 | 0.0 |
Germ-Line Mutation | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Loss of Heterozygosity | 3 | 0.0 |
Mutation | 11 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 43 | 0.0 |
Prognosis | 2 | 0.0 |
Prospective Studies | 3 | 0.0 |
*Antigens, Bacterial | 5 | 8.0 |
Cell Division | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Comparative Study | 20 | 0.0 |
English Abstract | 9 | 0.0 |
Erythrocyte Count | 2 | 2.0 |
Exons | 2 | 0.0 |
Gene Frequency | 5 | 0.0 |
Heterozygote | 9 | 0.0 |
Hypercholesterolemia, Familial/*genetics | 4 | 9.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Receptors, LDL/*genetics | 6 | 3.0 |
Anticholesteremic Agents/*therapeutic use | 3 | 5.0 |
Cholesterol/blood | 4 | 0.0 |
Electrocardiography | 2 | 0.0 |
Simvastatin/*therapeutic use | 2 | 8.0 |
Prevalence | 2 | 0.0 |
Pedigree | 12 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Child, Preschool | 15 | 0.0 |
Complement 3/metabolism | 2 | 0.0 |
Complement 3b/metabolism | 3 | 2.0 |
Complement Activation | 3 | 1.0 |
Phagocytosis | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Blotting, Western | 5 | 0.0 |
Child | 19 | 0.0 |
Complement Factor H/*analysis | 2 | 100.0 |
Infant | 12 | 0.0 |
Cell Line | 11 | 0.0 |
*Complement Activation | 3 | 0.0 |
Consensus Sequence | 6 | 0.0 |
In Vitro | 6 | 0.0 |
Repetitive Sequences, Amino Acid | 6 | 4.0 |
Complement Factor H/*chemistry/*metabolism | 2 | 100.0 |
Molecular Weight | 5 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
*Bacterial Outer Membrane Proteins | 2 | 12.0 |
Heparin/chemistry | 2 | 13.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Genetic Markers | 2 | 0.0 |
Insulin Resistance | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Incidence | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Complement Factor H/*genetics | 3 | 75.0 |
Cohort Studies | 2 | 0.0 |
Linear Models | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
*Evolution, Molecular | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Heart Rate | 8 | 3.0 |
Respiratory Function Tests | 2 | 1.0 |
Lipids/blood | 5 | 0.0 |
Reference Values | 5 | 0.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Mice | 10 | 0.0 |
Protein Sorting Signals/genetics | 2 | 2.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 5 | 0.0 |
Protein Conformation | 3 | 0.0 |
Sex Factors | 3 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
*Loss of Heterozygosity | 2 | 0.0 |
Neoplasms/*genetics | 2 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Carcinoma, Renal Cell/*genetics | 2 | 2.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Kidney Neoplasms/*genetics | 3 | 1.0 |
Logistic Models | 2 | 0.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Heat | 3 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Consensus Sequence/immunology | 2 | 66.0 |
Heparin/pharmacology | 3 | 1.0 |
Peptide Mapping | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Bacterial Proteins/*analysis | 2 | 18.0 |
Blood Pressure | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Acute Disease | 2 | 0.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Complement 4b/metabolism | 2 | 8.0 |
*Complement Inactivators | 3 | 3.0 |
*Glycoproteins | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Fibroblasts | 4 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Risk | 2 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Hypercholesterolemia, Familial/*diagnosis/drug therapy/genetics | 3 | 100.0 |
*Mutation | 4 | 0.0 |
Sequence Analysis, Protein | 2 | 1.0 |
Lipoproteins/*blood | 2 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
Heparin/metabolism | 2 | 1.0 |
Binding Sites/genetics/immunology | 3 | 6.0 |
Sequence Deletion/immunology | 2 | 13.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 5 | 0.0 |
Streptococcus pyogenes/*immunology | 2 | 10.0 |
Antigens, Bacterial/chemistry/*immunology | 2 | 28.0 |
Complement Factor H/*physiology | 2 | 100.0 |
Follow-Up Studies | 2 | 0.0 |
Simvastatin | 2 | 6.0 |
Chromosome Mapping | 5 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Rats | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Homozygote | 4 | 0.0 |
Infant, Newborn | 6 | 0.0 |
Lipoproteins/blood | 3 | 0.0 |
Pregnancy | 3 | 0.0 |
Fibroblasts/metabolism | 4 | 0.0 |
Lipoproteins, LDL/*metabolism | 2 | 1.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Models, Biological | 2 | 0.0 |
Protein Binding/genetics/immunology | 2 | 2.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Fumarate Hydratase/*genetics | 6 | 75.0 |
Leiomyoma/*genetics | 2 | 10.0 |
Uterine Neoplasms/*genetics | 2 | 5.0 |
Alleles | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Kinetics | 4 | 0.0 |
Receptors, LDL/genetics/*metabolism | 2 | 7.0 |
Body Height/*drug effects | 2 | 12.0 |
Turner Syndrome/*drug therapy/physiopathology | 2 | 100.0 |
Socioeconomic Factors | 2 | 1.0 |
Triglycerides/blood | 2 | 0.0 |
Hypercholesterolemia, Familial/blood/*drug therapy | 2 | 14.0 |
Iloprost | 2 | 40.0 |
Platelet Aggregation/drug effects | 2 | 0.0 |
Complement Factor H | 3 | 3.0 |
Energy Metabolism | 2 | 1.0 |
Complement 3b/*metabolism | 2 | 2.0 |
Free Radicals | 2 | 1.0 |
Genes, MHC Class II | 2 | 0.0 |
Partial Pressure | 2 | 4.0 |
*Exertion | 3 | 1.0 |
Oxygen Consumption | 5 | 2.0 |
Respiration | 2 | 3.0 |
*Chromosomes, Human, 1-3 | 3 | 5.0 |
*Chromosome Aberrations | 2 | 0.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Fumarate Hydratase/metabolism | 2 | 66.0 |
*Genes | 2 | 0.0 |
Phosphoglucomutase/metabolism | 2 | 40.0 |
Phosphogluconate Dehydrogenase/metabolism | 2 | 18.0 |
UTP-Glucose-1-Phosphate Uridylyltransferase/metabolism | 2 | 100.0 |
